Can cosentyx affect infection immunity post vaccination?

How does Cosentyx interact with vaccines?

Cosentyx (secukinumab) is a monoclonal antibody that selectively inhibits interleukin-17A. It treats psoriasis, psoriatic arthritis, and ankylosing spondylitis. By blocking IL-17A, Cosentyx weakens the body's natural defense against bacteria and fungi, raising infection risk.

What happens if you get vaccinated while on Cosentyx?

Cosentyx does not directly interfere with the development of immunity after vaccination. Available clinical data show that patients on Cosentyx still develop adequate antibody responses to most vaccines, including influenza and pneumococcal vaccines. Clinical studies have not reported any significant reduction in immune response to vaccination.

Does Cosentyx raise infection risk after vaccination?

Cosentyx increases susceptibility to infections overall. Patients must watch for signs of serious infections, such as persistent fever or new infections that are not resolving. Cosentyx is contraindicated in patients with active tuberculosis. It also recommends screening for latent TB before treatment begins.

Can live vaccines be given with Cosentyx?

Cosentyx is not recommended with live vaccines. The drug's mechanism of blocking IL-17A may impair the ability to control live attenuated viruses or bacteria. Clinicians generally avoid live vaccines such as MMR, oral polio, and varicella during treatment and for several months after.

What alternatives exist if live vaccines are needed?

Patients who require live vaccines before starting Cosentyx can complete the vaccination schedule before treatment begins. For patients already on Cosentyx, doctors may pause treatment to allow live vaccines, but this Entscheidung is made on a per-patient basis.

How long does Cosentyx stay in the system?

Cosentyx has a half-life of approximately 27 days. It remains in the body for 4–5 half-lives, roughly 110–135 days, after the final dose. This time frame is useful for planning vaccinations.

How does Cosentyx compare with other biologics?

Cosentyx is an IL-17 inhibitor. Other biologics that inhibit the IL-17 pathway, such as Taltz (ixekizumab) and Siliq (brodalumab), have similar warnings about live vaccines and infection risk. TNF inhibitors such as Humira and Enbrel also require caution with live vaccines.

When does Cosentyx patent expire?

Cosentyx has an active patent until March 2026. [1]